English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/228179
Share/Impact:
Statistics
logo share SHARE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Tibolone as Hormonal Therapy and Neuroprotective Agent

AuthorsDel Río, J.P.; Molina, S.; Hidalgo-Lanussa, O.; García-Segura, Luis M.
Keywordstibolone
hormonal therapy
central nervous system
neuroprotection
breast
uterus
Issue Date 10
PublisherCell Press
CitationTRENDS IN ENDOCRINOLOGY AND METABOLISM (2020)
AbstractTibolone (TIB), a selective tissue estrogenic activity regulator (STEAR) in clinical use by postmenopausal women, activates hormonal receptors in a tissue-specific manner. Estrogenic activity is present mostly in the brain, vagina, and bone, while the inactive forms predominate in the endometrium and breast. Conflicting literature on TIB's actions has been observed. While it has benefits for vasomotor symptoms, bone demineralization, and sexual health, a higher relative risk of hormone-sensitive cancer has been reported. In the brain, TIB can improve mood and cognition, neuroinflammation, and reactive gliosis. This review aims to discuss the systemic effects of TIB on peri- and post-menopausal women and its role in the brain. We suggest that TIB is a hormonal therapy with promising neuroprotective properties.
Publisher version (URL)http://dx.doi.org/10.1016/j.tem.2020.04.007
URIhttp://hdl.handle.net/10261/228179
Identifiersdoi: 10.1016/j.tem.2020.04.007
issn: 1879-3061
Appears in Collections:(IC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.